Navigation Links
VisEn Launches New VivoTag(R) 645 Fluorescence Molecular Imaging Label
Date:5/5/2010

BEDFORD, Mass., May 5 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence imaging from research through medicine, announced today the commercial launch of its new VivoTag® 645 red fluorescent dye for optimized labeling of biomolecules in a broad range of in vitro and in vivo research applications.  

The new VivoTag 645 represents VisEn's first agent offering in the lower-red wavelengths, enabling optimized and integrated imaging applications in both in vivo and in vitro research areas.  The VivoTag 645 is specifically designed for efficient and robust labeling of biomolecules, and is optimized for broad in vitro and in vivo imaging performance, including system compatibility, superior brightness, biocompatibility and stability in biological environments.  

"Our new VivoTag 645 represents an important evolution in our fluorescent imaging agent product line," said Kirtland Poss, President and CEO of VisEn Medical. "This new label is designed to be well-suited for applications both in vitro and in vivo research and we look forward to working closely with our customers in continually advancing these integrated research areas."

The new VivoTag 645 is particularly well suited for labeling and imaging of proteins, antibodies, and small molecules in a range of research areas.  The fluorescence wavelength is matched for biological imaging applications on in vitro and in vivo fluorescence systems, including advanced microscopes, high content imaging and flow cytometry systems. It is also optimized for use with VisEn's fluorescence tomography FMT™ imaging systems which also have expanded wavelength capabilities to enable quantitative imaging of up to four channels and four different biomarkers of interest in vivo.

VisEn's proprietary fluorescence imaging agents and labels are designed to provide the industry's broadest and most robust range of biologically-specific imaging readouts.  VisEn offers over 35 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways.  VisEn agent brands include ProSense®, IntegriSense™, AngioSense™, OsteoSense®, MMPSense™, GastroSense™, ReninSenseTM, Annexin-VivoTM, and the FAST™ line of imaging agents including Cat K FAST™ and Cat B FAST™.  VisEn also offers specialized lines of agent labeling platforms, including its proprietary VivoTag® fluorescence labeling dyes and its NanoSpark® nanoparticles for customized fluorescence agent labeling.  They are all designed and optimized specifically for superior biocompatibility, brightness, stability and performance in biological imaging applications including in vitro, cell, tissue and in vivo imaging applications.  

All VisEn agents and labels are designed for in vivo biomarker quantification using VisEn's Fluorescence Molecular Tomography (FMT) imaging systems, or for general use along with other non-quantitative fluorescence in vivo imaging systems.  VisEn agents are also designed to enable complementary in vitro biomarker readouts in cells and tissues using standard fluorescence microscopy and other cellular-based imaging systems.  With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking preclinical research into clinical medicine.

About VisEn Medical Inc.

VisEn's in vivo fluorescence imaging technologies, including its RED Fluorescence Agent Portfolio and its Fluorescence Molecular Tomography (FMT) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo.  VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies worldwide in applications including oncology, arthritis, cardiovascular disease, skeletal disorders, and pulmonary disease.  The Company also works with large pharmaceutical and clinical partners to design ranges of tailored molecular imaging agents and applications designed for their specific preclinical and clinical research areas. Additional information can be found at www.visenmedical.com.


'/>"/>
SOURCE VisEn Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. VisEn Launches New Annexin-Vivo 750 Fluorescence Molecular Imaging Agent
2. VisEn Launches New Cat-K FAST(TM) Fluorescence Molecular Imaging Agent
3. VisEn Launches Next-Generation Fast (Fluorescence Activatible Sensor Technology) Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo
4. VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
5. VisEn Medical Raises $7 Million in Series B Financing
6. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
7. BellBrook Labs Launches Compound Profiling Services with High Content 3D Invasion Assay
8. Ansell Launches Worldss First Antimicrobial Surgical Glove
9. ChromaDex Launches pTeroPure Pterostilbene
10. Vermont Launches Renewable Energy Atlas
11. DNA-Planet Launches New Service for Customer-Individual Indirect DNA Paternity Testing and Kinship Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... has an active R&D program for the development ... the Group has a unique research and development center in ... developing Bio Control products. Stockton has ... and regulatory guidelines, and is active in more than 35 ... Stockton,s flagship product Timorex Gold ® ...
(Date:2/6/2016)... ... February 06, 2016 , ... Contact:, Abby Mitchell, Communications Manager, ... Education Sponsors Teacher Training Program , Bite of Science Dinner Event to Strengthen ... Excellence in Education (CEE) will sponsor a Bite of Science professional enrichment session, ...
(Date:2/5/2016)... 2016 Amarantus BioScience Holdings, Inc. ... on developing products for Regenerative Medicine, Neurology and Orphan ... Designation (RPDD) from the US Food and Drug Administration ... was previously granted orphan drug designation (ODD) by the ... BioScience Holdings, Inc. (OTCQB: AMBS), a ...
(Date:2/4/2016)... RICHMOND, Calif. , Feb. 4, 2016  Sangamo ... therapeutic genome editing, announced today that Edward Lanphier ... an update on the progress of Sangamo,s ZFP Therapeutic ... company,s business strategy at 2:40 pm ET on Thursday, ... Annual Global Healthcare Conference. The conference is being ...
Breaking Biology Technology:
(Date:1/22/2016)... 22, 2016 ... of the  "Global Behavioral Biometric Market ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ... Biometric Market 2016-2020"  report to their ... Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ...
(Date:1/20/2016)... , Jan. 20, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... significant achievements are the result of the company,s laser ... iMedNet eClinical , it,s comprehensive, easy-to-use and highly ... --> Key MedNet growth achievements in 2015 ...
(Date:1/13/2016)... New York , January 13, 2016 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2023. According to the ... in 2014 and is anticipated to reach US$1,625.8 mn ... 2015 to 2023. In terms of volume, the biometric ...
Breaking Biology News(10 mins):